TRIML1

gene

On this page

Also known as FLJ36180RNF209

Summary

TRIML1 (tripartite motif family like 1, HGNC:26698) is a protein-coding gene on chromosome 4q35.2, encoding Probable E3 ubiquitin-protein ligase TRIML1 (Q8N9V2). Probable E3 ubiquitin-protein ligase which plays an important role in blastocyst development.

The protein encoded by this gene is a tripartite motif family protein with similarities to E3 ubiquitin-protein ligases. While the function of the encoded protein has not been determined, the orthologous protein in mouse has been shown to bind ubiquitin-specific protease 5 and is involved in the blastocyst development stage.

Source: NCBI Gene 339976 — RefSeq curated summary.

At a glance

GWAS associations: 2
Clinical variants (ClinVar): 91 total
MANE Select transcript: NM_178556

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:26698
Approved symbol	TRIML1
Name	tripartite motif family like 1
Location	4q35.2
Locus type	gene with protein product
Status	Approved
Aliases	FLJ36180, RNF209
Ensembl gene	ENSG00000184108
Ensembl biotype	protein_coding
OMIM	620979
Entrez	339976

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 2 protein_coding_CDS_not_defined, 1 protein_coding

ENST00000332517, ENST00000507581, ENST00000512233

RefSeq mRNA: 1 — MANE Select: NM_178556 NM_178556

CCDS: CCDS3851

Canonical transcript exons

ENST00000332517 — 6 exons

Exon	Start	End
ENSE00001294398	188146822	188147743
ENSE00001294959	188139441	188139966
ENSE00001306909	188142252	188142482
ENSE00001315904	188140528	188140623
ENSE00003477987	188143838	188143860
ENSE00003636255	188144036	188144133

Expression profiles

Bgee: expression breadth broad, 22 present calls, max score 84.61.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.0252 / max 10.5635, expressed in 9 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
50932	0.0187	6
203459	0.0065	3

Top tissues by expression

225 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	84.61	gold quality
left testis	UBERON:0004533	76.71	gold quality
right testis	UBERON:0004534	75.22	gold quality
testis	UBERON:0000473	74.47	gold quality
sperm	CL:0000019	71.43	silver quality
myocardium	UBERON:0002349	58.42	gold quality
adult organism	UBERON:0007023	55.50	silver quality
endothelial cell	CL:0000115	52.70	gold quality
mucosa of sigmoid colon	UBERON:0004993	52.17	gold quality
tendon of biceps brachii	UBERON:0008188	51.86	gold quality
oocyte	CL:0000023	49.93	gold quality
colonic mucosa	UBERON:0000317	48.09	gold quality
nipple	UBERON:0002030	47.46	gold quality
lower lobe of lung	UBERON:0008949	45.16	silver quality
placenta	UBERON:0001987	44.12	gold quality
amniotic fluid	UBERON:0000173	44.03	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	43.37	gold quality
gingiva	UBERON:0001828	43.21	gold quality
dorsal root ganglion	UBERON:0000044	43.12	gold quality
secondary oocyte	CL:0000655	42.57	gold quality
esophagus squamous epithelium	UBERON:0006920	41.70	gold quality
Brodmann (1909) area 23	UBERON:0013554	41.70	gold quality
vastus lateralis	UBERON:0001379	41.41	gold quality
trigeminal ganglion	UBERON:0001675	41.38	gold quality
quadriceps femoris	UBERON:0001377	41.37	gold quality
superficial temporal artery	UBERON:0001614	41.33	gold quality
nasal cavity epithelium	UBERON:0005384	41.31	gold quality
biceps brachii	UBERON:0001507	41.21	gold quality
palpebral conjunctiva	UBERON:0001812	41.10	gold quality
mucosa of paranasal sinus	UBERON:0005030	40.98	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.12

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

8 targeting TRIML1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-205-3P	99.92	69.92	3165
HSA-MIR-6848-3P	99.64	66.49	885
HSA-MIR-6843-3P	99.26	66.42	915
HSA-MIR-5100	99.11	67.52	1098
HSA-MIR-1288-5P	98.85	67.01	734
HSA-MIR-633	98.35	69.45	1167
HSA-MIR-3622A-3P	97.06	66.43	1000
HSA-MIR-3622B-3P	96.82	66.36	988

Literature-anchored findings (GeneRIF, showing 1)

This paper describes the mouse ortholog of the human TRIML1 gene. (PMID:19156909)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Triml1	ENSMUSG00000031651
rattus_norvegicus	Triml1	ENSRNOG00000014502

Paralogs (80): MID2 (ENSG00000080561), TRIM9 (ENSG00000100505), MID1 (ENSG00000101871), MEFV (ENSG00000103313), TRIM35 (ENSG00000104228), TRIM14 (ENSG00000106785), TRIM37 (ENSG00000108395), TRIM2 (ENSG00000109654), TRIM3 (ENSG00000110171), TRIM38 (ENSG00000112343), TRIM62 (ENSG00000116525), TRIM67 (ENSG00000119283), TRIM32 (ENSG00000119401), BSPRY (ENSG00000119411), TRIM25 (ENSG00000121060), TRIM6 (ENSG00000121236), TRIM24 (ENSG00000122779), TRIM51 (ENSG00000124900), TRIM28 (ENSG00000130726), TRIM21 (ENSG00000132109), TRIM5 (ENSG00000132256), TRIM22 (ENSG00000132274), TRIM47 (ENSG00000132481), TRIM45 (ENSG00000134253), TRIM29 (ENSG00000137699), TRIM54 (ENSG00000138100), PML (ENSG00000140464), TRIM65 (ENSG00000141569), TRIM43B (ENSG00000144010), TRIM43 (ENSG00000144015), TRIM7 (ENSG00000146054), TRIM41 (ENSG00000146063), TRIM50 (ENSG00000146755), TRIM4 (ENSG00000146833), TRIM55 (ENSG00000147573), TRIM48 (ENSG00000150244), TRIM36 (ENSG00000152503), TRIM11 (ENSG00000154370), TRIM74 (ENSG00000155428), TRIM42 (ENSG00000155890)

Protein

Protein identifiers

Probable E3 ubiquitin-protein ligase TRIML1 — Q8N9V2 (reviewed: Q8N9V2)

Alternative names: RING finger protein 209, RING-type E3 ubiquitin transferase TRIML1, Tripartite motif family-like protein 1

All UniProt accessions (1): Q8N9V2

UniProt curated annotations — full annotation on UniProt →

Function. Probable E3 ubiquitin-protein ligase which plays an important role in blastocyst development.

Subunit / interactions. Interacts with USP5.

Pathway. Protein modification; protein ubiquitination.

RefSeq proteins (1): NP_848651* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001841	Znf_RING	Domain
IPR001870	B30.2/SPRY	Domain
IPR003877	SPRY_dom	Domain
IPR003879	Butyrophylin_SPRY	Domain
IPR006574	PRY	Domain
IPR013083	Znf_RING/FYVE/PHD	Homologous_superfamily
IPR013320	ConA-like_dom_sf	Homologous_superfamily
IPR017907	Znf_RING_CS	Conserved_site
IPR043136	B30.2/SPRY_sf	Homologous_superfamily
IPR050143	TRIM/RBCC	Family

Pfam: PF00622, PF13765, PF15227

UniProt features (7 total): coiled-coil region 2, sequence variant 2, chain 1, domain 1, zinc finger region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8N9V2-F1	86.29	0.63

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 36 (showing top): AAAYRNCTG_UNKNOWN, GOBP_DEFENSE_RESPONSE_TO_OTHER_ORGANISM, chr4q35, GOBP_POST_TRANSLATIONAL_PROTEIN_MODIFICATION, GATA1_02, GOMF_ACYLTRANSFERASE_ACTIVITY, GOMF_AMINOACYLTRANSFERASE_ACTIVITY, GOMF_UBIQUITIN_LIKE_PROTEIN_LIGASE_ACTIVITY, RAO_BOUND_BY_SALL4, GSE13229_IMM_VS_MATURE_NKCELL_DN, GOBP_PROTEIN_MODIFICATION_BY_SMALL_PROTEIN_CONJUGATION, GSE15659_NAIVE_VS_PTPRC_NEG_CD4_TCELL_DN, GSE15659_NAIVE_CD4_TCELL_VS_NONSUPPRESSIVE_TCELL_DN, GSE15659_NAIVE_CD4_TCELL_VS_ACTIVATED_TREG_DN, GSE15659_CD45RA_NEG_CD4_TCELL_VS_ACTIVATED_TREG_DN

GO Biological Process (2): protein ubiquitination (GO:0016567), innate immune response (GO:0045087)

GO Molecular Function (5): zinc ion binding (GO:0008270), ubiquitin protein ligase activity (GO:0061630), protein binding (GO:0005515), transferase activity (GO:0016740), metal ion binding (GO:0046872)

GO Cellular Component (1): cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein modification by small protein conjugation	1
immune response	1
defense response to symbiont	1
transition metal ion binding	1
ubiquitin-protein transferase activity	1
ubiquitin-like protein ligase activity	1
binding	1
catalytic activity	1
cation binding	1
intracellular anatomical structure	1
cellular anatomical structure	1

Protein interactions and networks

STRING

452 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TRIML1	FAM149A	A5PLN7	583
TRIML1	BEND5	Q7L4P6	582
TRIML1	FRG1	Q14331	547
TRIML1	ZFP42	Q96MM3	527
TRIML1	ATP10D	Q9P241	514
TRIML1	FANCD2OS	Q96PS1	514
TRIML1	DPEP2	Q9H4A9	500
TRIML1	FRG2	Q64ET8	479
TRIML1	CCDC110	Q8TBZ0	433
TRIML1	OAZ3	Q9UMX2	430
TRIML1	MTNR1A	P48039	419
TRIML1	GALNT18	Q6P9A2	418
TRIML1	ZSWIM2	Q8NEG5	417
TRIML1	CFAP96	A7E2U8	407
TRIML1	SHROOM3	Q8TF72	399

IntAct

3 interactions, top by confidence:

A	B	Type	Score
TRIML1	MNAT1	psi-mi:“MI:0915”(physical association)	0.370
TRIML1	RBCK1	psi-mi:“MI:0915”(physical association)	0.370

BioGRID (8): TRIML1 (Affinity Capture-MS), TRIML1 (Affinity Capture-MS), TRIML1 (Affinity Capture-MS), USP5 (Reconstituted Complex), TRIML1 (Affinity Capture-Western), APP (Reconstituted Complex), TRIML1 (Two-hybrid), TRIML1 (Two-hybrid)

ESM2 similar proteins: A0A0G2JMD5, A0A0J9YX57, A2A368, A2A9R3, A6NCF6, A6NK02, A8MXT2, D9I2F9, D9I2G3, D9I2H0, O15479, O15480, O15481, O60809, O95521, P14373, P25233, P43355, P43356, P43357, P43358, P43360, P43361, P43362, P43363, P43364, P43365, P43366, Q2LKU9, Q2LKW6, Q4R998, Q5PPP4, Q5SWL7, Q62191, Q6AY37, Q6AZZ1, Q8BQR7, Q8BVP1, Q8K243, Q8N7X4

Diamond homologs: A0JN74, A6NCK2, A6NDI0, A6NGJ6, A6NI03, A6NK02, A6NLI5, B1H278, C9J1S8, K7N6K2, O00635, O15553, O19085, O77666, P0CI25, P0CI26, P14373, P15533, P18892, P19474, Q02084, Q0PF16, Q12899, Q13410, Q1ACD5, Q1ACD6, Q1ACD7, Q1ACD8, Q1XHU0, Q2T9Z0, Q2YEM8, Q2YEM9, Q2YEN0, Q2YEN2, Q3UWZ0, Q3ZEE5, Q495X7, Q587N6, Q587N7, Q58DK8

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
Ub:E2	“up-regulates activity”	TRIML1	ubiquitination

Disease & clinical

Clinical variants and AI predictions

ClinVar

91 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	73
Likely benign	9
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

884 predictions. Top by Δscore:

Variant	Effect	Δscore
4:188139965:GA:G	donor_gain	1.0000
4:188139967:G:GG	donor_gain	1.0000
4:188140008:C:G	donor_gain	1.0000
4:188142479:TGAGG:T	donor_loss	1.0000
4:188142482:GGTGA:G	donor_loss	1.0000
4:188142484:T:A	donor_loss	1.0000
4:188144030:TTGCA:T	acceptor_loss	1.0000
4:188144031:TGCA:T	acceptor_loss	1.0000
4:188144032:GCA:G	acceptor_loss	1.0000
4:188144034:A:AG	acceptor_gain	1.0000
4:188144034:AG:A	acceptor_gain	1.0000
4:188144035:G:GG	acceptor_gain	1.0000
4:188144035:GG:G	acceptor_gain	1.0000
4:188144035:GGA:G	acceptor_gain	1.0000
4:188144035:GGAGC:G	acceptor_gain	1.0000
4:188144129:CAGCA:C	donor_gain	1.0000
4:188144130:AGCA:A	donor_gain	1.0000
4:188144130:AGCAG:A	donor_loss	1.0000
4:188144131:GCA:G	donor_gain	1.0000
4:188144131:GCAG:G	donor_gain	1.0000
4:188144132:CA:C	donor_gain	1.0000
4:188144133:AG:A	donor_loss	1.0000
4:188144134:G:GG	donor_gain	1.0000
4:188144135:TAA:T	donor_loss	1.0000
4:188146820:A:AG	acceptor_gain	1.0000
4:188146820:AGC:A	acceptor_gain	1.0000
4:188146820:AGCG:A	acceptor_gain	1.0000
4:188146821:G:GG	acceptor_gain	1.0000
4:188146821:GCG:G	acceptor_gain	1.0000
4:188146821:GCGG:G	acceptor_gain	1.0000

AlphaMissense

3095 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
4:188147022:T:A	W353R	0.998
4:188147022:T:C	W353R	0.998
4:188146992:T:A	W343R	0.994
4:188146992:T:C	W343R	0.994
4:188147223:T:C	F420L	0.994
4:188147225:C:A	F420L	0.994
4:188147225:C:G	F420L	0.994
4:188147024:G:C	W353C	0.992
4:188147024:G:T	W353C	0.992
4:188139661:T:C	F35L	0.990
4:188139663:T:A	F35L	0.990
4:188139663:T:G	F35L	0.990
4:188146935:T:C	F324L	0.990
4:188146937:T:A	F324L	0.990
4:188146937:T:G	F324L	0.990
4:188147057:A:C	R364S	0.990
4:188147057:A:T	R364S	0.990
4:188147098:T:C	L378P	0.989
4:188147301:T:C	S446P	0.989
4:188139604:T:C	C16R	0.988
4:188146861:T:C	L299P	0.988
4:188146954:T:A	V330E	0.988
4:188146994:G:C	W343C	0.988
4:188146994:G:T	W343C	0.988
4:188147224:T:C	F420S	0.988
4:188147299:T:C	F445S	0.988
4:188139658:A:C	S34R	0.986
4:188139660:C:A	S34R	0.986
4:188139660:C:G	S34R	0.986
4:188147191:T:A	V409D	0.986

dbSNP variants (sampled 300 via entrez): RS1000013092 (4:188150240 C>A,T), RS1000673334 (4:188135357 C>T), RS1000699918 (4:188150376 G>A,T), RS1000835991 (4:188137243 A>G), RS1000969201 (4:188149457 C>T), RS10010192 (4:188136458 C>G,T), RS1001252124 (4:188149715 C>T), RS1001653430 (4:188140364 C>G,T), RS1001679105 (4:188140388 C>T), RS1001882044 (4:188144964 A>C), RS10019679 (4:188145248 G>A,C), RS1002211851 (4:188148669 C>T), RS1002264220 (4:188148498 A>G), RS1002312090 (4:188149570 C>A,T), RS1002378202 (4:188139020 C>A,T)

Disease associations

OMIM: gene MIM:620979 | disease phenotypes:

GenCC curated gene-disease

Mondo (3): prostate cancer (MONDO:0008315), primary ovarian failure (MONDO:0005387), neurodevelopmental disorder (MONDO:0700092)

Orphanet (2): Familial prostate cancer (Orphanet:1331), NON RARE IN EUROPE: Primary ovarian failure (Orphanet:619)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST002549_6	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels)	7.000000e-09
GCST002741_2	Polycystic ovary syndrome	6.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0005658	response to selective serotonin reuptake inhibitor

MeSH disease descriptors (3)

Descriptor	Name	Tree numbers
D065886	Neurodevelopmental Disorders	F03.625
D016649	Primary Ovarian Insufficiency	C12.050.351.500.056.630.750; C12.100.250.056.630.750; C19.391.630.750
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

9 total (human), top 9 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	affects cotreatment, decreases methylation	1
arsenite	increases methylation	1
abrine	increases expression	1
Fulvestrant	affects cotreatment, decreases methylation	1
Acetaminophen	increases expression	1
Benzo(a)pyrene	decreases methylation	1
Capsaicin	increases expression	1
Valproic Acid	increases methylation	1
Aflatoxin B1	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer

Disease cohort memberships (association, not causation — diseases whose associated-gene cohort lists this gene; a subset are also under Associated diseases): polycystic ovary syndrome